Camegliptin(CAS:813452-18-5)

Carmegliptin (CAS 813452-18-5) is a new-generation structurally optimized long-acting dipeptidyl peptidase 4 inhibitor hypoglycemic API. Endowed with core advantages of high target selectivity, prolonged efficacy duration and superior medication safety, it has become an innovative and essential raw material for long-term chronic management of type 2 diabetes, widely applied in the research and development of new long-acting hypoglycemic preparations, industrial production of generic drugs, and pharmacological research on endocrine metabolism. With stable chemical structure and excellent physical and chemical properties, Carmegliptin strictly complies with USP, EP and domestic pharmacopoeia standards in terms of related substances, chiral impurities, residual solvents and heavy metals. It features high purity and tiny batch differences, stably supporting the large-scale production of mainstream dosage forms such as oral conventional tablets and long-acting sustained-release tablets, standing as a highly competitive high-quality variety in the hypoglycemic API industry.

In terms of core pharmacological mechanism, Carmegliptin builds a safe and stable novel hypoglycemic pathway through highly specific targeted inhibition of DPP4. Endogenous incretins GLP-1 and GIP secreted by intestinal tract are core hormones regulating blood glucose, which adjust pancreatic secretion strictly according to glucose concentration. However, natural incretins are rapidly degraded by DPP4 enzymes with extremely short action time. After oral absorption, Carmegliptin reversibly and selectively binds to the active site of DPP4, potently blocking incretin degradation and significantly increasing the concentration and action duration of active incretins in vivo. Its unique glucose-dependent regulatory mechanism serves as the biggest highlight: the hypoglycemic pathway is only activated under hyperglycemia to promote insulin secretion from pancreatic β-cells, inhibit glucagon release from α-cells, reduce hepatic glucose output and accelerate peripheral glucose metabolism. When blood glucose returns to normal, the regulatory effect automatically weakens without interfering blood glucose homeostasis, fundamentally eliminating drug-induced hypoglycemia and achieving far higher safety than traditional sulfonylurea APIs.

Clinically, Carmegliptin is applicable to most patients with mild and moderate type 2 diabetes, especially suitable for middle-aged and elderly chronic patients with large blood glucose fluctuations, elevated postprandial blood glucose and demands for long-term stable glycemic control. For newly diagnosed early type 2 diabetes, monotherapy effectively reduces fasting blood glucose, postprandial blood glucose and glycated hemoglobin, stabilizes glycemic rhythm and delays disease progression. For patients with poor glycemic control with single metformin, Carmegliptin can be freely combined with metformin to form a complementary hypoglycemic regimen, synergistically optimizing all-day blood glucose indicators, reducing single-drug dosage dependence and lowering adverse reactions such as gastrointestinal disorders and metabolic disturbance. Meanwhile, it has no impact on body weight and almost no risk of sodium and water retention, showing excellent adaptability for diabetic patients complicated with obesity, dyslipidemia and mild renal impairment. Long-term medication improves overall metabolic status and reduces the risk of long-term diabetic vascular complications.

In terms of industrial production and medication safety, optimized synthetic routes and advanced purification technologies ensure mature and stable production of Carmegliptin with strict impurity control and controllable mass production costs, supporting long-term stable bulk supply and meeting the demands of domestic and foreign pharmaceutical factories for preparation production and new drug application. It possesses high oral bioavailability and mild in-vivo metabolism without obvious liver and kidney cumulative toxicity. The incidence of adverse reactions under conventional doses is extremely low with excellent long-term tolerance. Compared with traditional DPP4 inhibitors such as sitagliptin and saxagliptin, Carmegliptin has more prominent long-acting performance, higher targeting accuracy and fewer side effects, with distinct differentiated advantages in long-acting hypoglycemic preparations and refined chronic disease treatment. With the continuously rising global prevalence of type 2 diabetes and expanding market demand for long-acting, safe and stable hypoglycemic raw materials, Carmegliptin maintains broad and stable development prospects in pharmaceutical R&D and industrial production relying on its excellent comprehensive performance.